Biomarkers in lung cancer screening: the importance of study design

Eur Respir J. 2021 Jan 14;57(1):2004367. doi: 10.1183/13993003.04367-2020. Print 2021 Jan.

David R Baldwin^{1

2}, Matthew E Callister^{3

4}, Philip A Crosbie^{5

6}, Emma L O'Dowd^{7

2}, Robert C Rintoul^{8

9}, Hilary A Robbins¹⁰, Robert J C Steele¹¹

¹ Respiratory Medicine, Nottingham University Hospitals, Nottingham, UK david.baldwin@nottingham.ac.uk.
² University of Nottingham, Nottingham, UK.
³ Leeds Teaching Hospitals, Leeds, UK.
⁴ University of Leeds, St James's University Hospital, Leeds, UK.
⁵ Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK.
⁶ Manchester Thoracic Oncology Centre, North West Lung Centre, Manchester University NHS Foundation Trust, Manchester, UK.
⁷ Respiratory Medicine, Nottingham University Hospitals, Nottingham, UK.
⁸ Dept of Oncology, University of Cambridge, Cambridge, UK.
⁹ Dept of Thoracic Oncology, Royal Papworth Hospital, Cambridge, UK.
¹⁰ Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France.
¹¹ UK National Screening Committee, Dept of Surgery, Ninewells Hospital, University of Dundee, Dundee, UK.

No abstract available

Publication types